Evidence map›Paper›PMID 40810151›Full record

ArticleACS pharmacology & translational science2025

Ponatinib Averts αCD40 Antibody Mediated Toxicity by Lowering MAPK38 Expression and Shows Proimmunogenic Effects in a Murine Tumor Model.

Vidit Gaur, Anjali Barnwal, Khushboo Singh, Witty Tyagi, Anita Nandi, Usmani Akif, Javed Miyan, Smrati Bhaduaria, Poonam Yadav, Avinash Bajaj and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Vidit GaurCentre for Biomedical Engineering, Indian Institute of Technology Delhi, New Delhi 110016, India.
Anjali BarnwalCentre for Biomedical Engineering, Indian Institute of Technology Delhi, New Delhi 110016, India.
Khushboo SinghCentre for Biomedical Engineering, Indian Institute of Technology Delhi, New Delhi 110016, India.
Witty TyagiMolecular Oncology Laboratory, National Institute of Immunology, Delhi 110067, India.ORCID https://orcid.org/0000-0002-6164-3523
Anita NandiMolecular Oncology Laboratory, National Institute of Immunology, Delhi 110067, India.
Usmani AkifDivision of Toxicology & Experimental Medicine, Central Drug Research Institute (CSIR), Lucknow 226031, India.
Javed MiyanDivision of Toxicology & Experimental Medicine, Central Drug Research Institute (CSIR), Lucknow 226031, India.
Smrati BhaduariaDivision of Toxicology & Experimental Medicine, Central Drug Research Institute (CSIR), Lucknow 226031, India.
Poonam YadavLaboratory of Nanotechnology and Chemical Biology, Regional Center for Biotechnology, Faridabad,Haryana 121001, India.ORCID https://orcid.org/0000-0003-0280-4136
Avinash BajajLaboratory of Nanotechnology and Chemical Biology, Regional Center for Biotechnology, Faridabad,Haryana 121001, India.ORCID https://orcid.org/0000-0002-1333-9316
Sanjeev DasMolecular Oncology Laboratory, National Institute of Immunology, Delhi 110067, India.
Prasenjit DasDepartment of Pathology, All India Institute of Medical Sciences, Delhi 110029, India.
Jayanta BhattacharyyaCentre for Biomedical Engineering, Indian Institute of Technology Delhi, New Delhi 110016, India.ORCID https://orcid.org/0000-0003-0202-4770

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of the agonist CD40 antibody (αCD40) is associated with several disadvantages including the cytokine release syndrome (CRS), hepatotoxicity, and induced PD-L1 expression. Previously, we have demonstrated that ponatinib, a tyrosine kinase inhibitor, could inhibit induced programmed death ligand 1 (PD-L1) expression. In this study, we showed that combinatorial treatment of αCD40 and ponatinib delayed the tumor growth and overall survival in mice bearing B16-F10 melanoma and 4T1 orthotopic tumors. The combination treatment increased the CD45

Indexed as

ponatinibprogrammed death ligand-1toxicitytumor microenvironmenttumor modulationαCD40

Identifiers

PMID40810151
PMCPMC12340643

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.